New Haven Biotech Inks $150 Million Cash Now - Deal
NEW HAVEN: Biohaven Pharmaceutical Holding Company Ltd. [NYSE: BHVN] based in the city's downtown has just shown the wisdom of its licensing and developing programs. Royalty Pharma a New York based bioscience investment firm has agreed to purchase a tiered, sales-based participation rights on future global net sales of products containing rimegepant, the company's migraine treatment in development.
from Biotech News
0 Comments